CN113456589A - 一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 - Google Patents
一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN113456589A CN113456589A CN202110796497.2A CN202110796497A CN113456589A CN 113456589 A CN113456589 A CN 113456589A CN 202110796497 A CN202110796497 A CN 202110796497A CN 113456589 A CN113456589 A CN 113456589A
- Authority
- CN
- China
- Prior art keywords
- parts
- patients
- spray
- ginseng
- infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 34
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 29
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 26
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000208340 Araliaceae Species 0.000 claims abstract description 35
- 235000008434 ginseng Nutrition 0.000 claims abstract description 35
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 34
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 34
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 21
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 21
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 19
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 18
- 229960000846 camphor Drugs 0.000 claims abstract description 17
- 229930008380 camphor Natural products 0.000 claims abstract description 17
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 16
- 238000002791 soaking Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000002107 myocardial effect Effects 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 210000002216 heart Anatomy 0.000 abstract description 17
- 208000002193 Pain Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 9
- 210000004072 lung Anatomy 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 210000000232 gallbladder Anatomy 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 210000003516 pericardium Anatomy 0.000 abstract description 3
- 235000019633 pungent taste Nutrition 0.000 abstract description 3
- 230000001568 sexual effect Effects 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 208000006820 Arthralgia Diseases 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229930182494 ginsenoside Natural products 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940089161 ginsenoside Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 4
- 229940117916 cinnamic aldehyde Drugs 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000001705 Mouth breathing Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000218195 Lauraceae Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940107131 ginseng root Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZGDVRBVTNMQMEX-LDHZKLTISA-N (8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylhept-6-en-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)=C)C)[C@@]1(C)CC2 ZGDVRBVTNMQMEX-LDHZKLTISA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000510667 Conioselinum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000005866 Exanthema Subitum Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000036485 Roseola Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001540751 Talaromyces ruber Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000002680 cardiopulmonary resuscitation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- -1 ligustrazine) Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,公开了一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用。中医认为心梗属于气滞血瘀证,是寒凝心脉致心阳脱。用活血化瘀,散寒宣痹,通络止痛,回阳救逆的药物方可解此病症。该急救喷雾剂是以樟脑:辛热归心经。散寒止痛开窍醒脑;桂枝:性温归心肺膀胱经,解肌温通经络助阳化气。人参:性温归心肺脾肾经,大补元气强心化瘀,安神回阳固脱。川芎:性辛温归肝胆心包经,行气开郁。用30度白酒浸泡,能使上述中药疗效倍增。白酒穿透力强作用快,酒精剌激性大,能剌激皮肤产生一系列的应激反应,并能促进血管对药物的吸收利用,还能活血化瘀提神醒脑回阳。
Description
技术领域
本发明属于医药技术领域,具体涉及一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用。
背景技术
随着现代工业科技的发展,人类的生活方式和饮食习惯发生了巨大的改变。人类不需强体力劳动就能衣食无忧,还有为了口感用工厂加工的方式改变食物的属性,添加化学调味剂及防腐剂,使人类心血管系统的疾病也逐年暴增,直接威胁到了人类的生命。而心梗病人的发病特点是:发病急,快。都是突然倒地、防不胜防。并能快速死亡。西医学认为只有四分钟的黄金抢救时间,过了这四分钟基本上很难活命。西医的临床表现有:突然胸闷气促,烦躁心季,心前区有压榨性疼痛,有种弊闷濒死的感觉。随后出现面色苍白,嘴唇发绀,大汗淋漓,血压下降休克等症状。而且西医目前还没很好的抢救药物及抢救方法。
目前国内外处理心梗脑梗的急救方法主要是:一、人工胸外按摩;人工口对口呼吸。二、药物有舌下含服的有硝酸甘油。
一、人工胸外按摩和口对口呼吸的急救方法,急救的效率低,会眈误病人的黄金抢救时间四分钟。还有如果病人在外突然倒地,周围没有医生,路人是否有懂得人工呼吸的呢?还有口对口呼吸的卫生问题,都会影响急救。
二、药物:一大瓶携带不方便,还有如果病人倒地就牙关紧闭,那路人操作极不方便,都会影响到病人的黄金抢救时间。
发明内容
为了解决现有技术存在的上述问题,本发明目的在于提供一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用。
本发明所采用的技术方案为:一种用于心梗脑梗患者的急救喷雾剂,所述喷雾剂主要由以下质量份数的原料制备得到:
樟脑0.5-4份,桂枝10-50份,人参5-30份和川芎10-50份。
作为优选地,所述喷雾剂主要由以下质量份数的原料制备得到:
樟脑1-3份,桂枝20-35份,人参10-20份和川芎20-35份。
作为优选地,所述喷雾剂主要由以下质量份数的原料制备得到:
樟脑2份,桂枝30份,人参15份和川芎30份。
樟脑,中药名。为樟科樟属植物樟Cinnamomumcamphora(L.)Presl.的枝、干、叶及根部,经提炼制成的颗粒状物结晶。具有除湿杀虫,温散止痛,开窍辟秽的功效。主治痧胀腹痛、吐泻、神昏、疥癣瘙痒、疮疡湿烂、寒湿脚气、牙痛、跌打伤痛等。味辛,性热;归心、脾经。
桂枝,中药名。为樟科樟胡椒属植物肉桂Cinnamomum cassia Presl的嫩枝。具有发汗解肌,温通经脉,助阳化气的功效。主治风寒感冒,寒凝血滞诸痛症,痰饮,蓄水证,心悸。味辛、甘,性温;归心、肺、膀胱经。本品含挥发油,其主要成分为桂皮醛等。另外尚含有酚类、有机酸、多糖、苷类、香豆精及鞣质等。桂枝水煎剂及桂皮醛有降温、解热作用。桂枝煎剂及乙醇浸液对金黄色葡萄球菌、白色葡萄球菌、伤寒杆菌、常见致病皮肤真菌、痢疾杆菌、肠炎沙门氏菌、霍乱弧菌、流感病毒等均有抑制作用。桂皮油、桂皮醛对结核杆菌有抑制作用,桂皮油有健胃、缓解胃肠道痉挛及利尿、强心等作用。桂皮醛有镇痛、镇静、抗惊厥作用。挥发油有止咳、祛痰作用。桂枝水煎液于白天小鼠灌服的LD50为624.7mg/kg,夜间灌服的LD50为773.6mg/kg。可见,桂枝对实验小鼠的毒性作用有显著的昼夜差异,白天的毒性和致死作用较夜间明显增强。
人参,中药名。为五加科人参属植物人参Panax ginseng C.A.Mey.的根。具有大补元气,补脾益肺,生津,安神益智的功效。主治气虚欲脱,脉微欲绝,脾气不足,中气下陷,肺虚喘咳,气短乏力,津伤口渴,虚热消渴,失眠健忘,心悸怔忡,血虚萎黄,阳痿宫冷等。味甘、微苦,性微温;归肺、脾经。本品含多种人参皂苷、挥发油、氨基酸、微量元素及有机酸、糖类、维生素等成分。 1、对神经系统的影响:人参能调节中枢神经系统兴奋过程和抑制过程的平衡,表现为小剂量兴奋中枢神经系统,大剂量则抑制中枢神经系统。2、改善脑组织代谢的作用:人参不但能改善大脑的兴奋过程而且也能改善其抑制过程,使两个过程恢复平衡。人参皂苷Rb、Rg对神经组织具有保护作用,对神经组织的生长和神经网络的建立具有促进作用。3、对记忆获得障碍的影响:人参对学习记忆的影响有双相性和成分依赖性。4、对垂体一肾上腺皮质系统的影响:人参有促进垂体一肾上腺皮质系统功能的作用。5、对心血管系统的影响:人参对多种动物心脏均有先兴奋后抑制,小量兴奋,大量抑制的作用。人参小剂量升压,大剂量降压。人参皂苷具有抗心律失常、保护心肌、降血脂、抗动脉硬化、扩张血管等作用。6、调节免疫功能的作用:人参皂苷可促进网状内皮系统吞噬功能,增加小鼠血清非特异性抗体的浓度。7、对血液系统的影响:人参或其提取物对骨髓的造血功能有刺激和保护作用,具有增强造血功能的作用。人参皂苷具有抑制血小板聚集的作用。8、抗菌作用:人参提取浓缩液对福氏痢疾杄菌 la型、乙型溶血性链球菌、产紫青霉菌均有抑制作用。较高浓度对金黄色葡萄球菌、大肠艾氏杄菌、炭疽杄菌、肺炎球菌、黑色曲霉菌、产黄青霉菌有抑制作用。9、此外,人参尚有一定的促进性腺功能、促进蛋白质合成、抗肿瘤、抗氧化、抗衰老、抗肝损伤、抗胃溃疡、抗疲劳、抗应激、抗辐射、抗突变、止血等作用。药理研究表明,人参及有效成分毒性均很小,动物实验皆可耐受很高的剂量。人参根粉小鼠灌胃给药的LD50大于5g/kg以上。人参浸膏小鼠皮下注射给药的LD50为16.5mg/kg。人参提取物或人参皂甙腹腔注射LD50在 300-700mg/kg之间。人参皂甙单体对小鼠腹腔注射的LD50分别为:Rb1 1110mg/kg,Rb2 305mg/kg,Rc;410mg/kg,Rd;325mg/kg,Re;465mg/kg,Rf1 340mg/kg,Rg1 1258mg/kg,Ro>1000mg/kg。人参多肽对小鼠静脉注射的LD50为1.62g/kg。人参多糖给小鼠口服30g/kg,观察48h,小鼠仅表现为安静,而无其他反应。人参多肽给大鼠皮下注射200mg/kg、400mg/kg、600mg/kg,给狗 200mg/kg、400mg/kg,在6个月内每日给药1次,均未引起明显毒性反应和过敏反应。一般药理实验表明,人参多肽对中枢神经系统、呼吸系统和心血管系统均无明显影响。尽管人参的动物实验表明其毒性很小,但因服用不当而产生毒副作用仍有所见,连续服用人参根粉可致失眠,抑郁,头痛,心悸,血压升高,性机能减退,体重减轻等。3%人参酊剂人内服100ml后,仅感到轻度不安和兴奋,内服200ml,可出现中毒现象:全身玫瑰疹、瘙痒、眩晕、头痛、体温升高及出血。
川芎,中药名,为伞形科藁本属植物川芎Ligusticumchuanxiong Hort.的干燥根茎。具有活血行气,祛风止痛的功效。主要用于心脉瘀阻之胸痹心痛、肝郁气滞之胁肋胀痛、肝血瘀阻之胸胁刺痛、瘀血阻滞之跌仆损伤、疮疡肿痛、月经不调、经闭痛经、产后瘀痛、恶露不行、多种头痛和风湿痹痛等。味辛,性温;归肝、胆、心包经。本品含生物碱(如川芎嗪),挥发油(主要为藁本内脂、香烩烯等),酚类物质(如阿魏酸),内脂素以及维生素A、叶酸、蔗糖、甾醇、脂肪油等。川芎嗪能扩张冠状动脉,增加冠状动脉血流量,改善心肌的血氧供应,并降低心肌的耗氧量;川芎嗪可扩张脑血管,降低血管阻力,显著增加脑及肢体血流量,改善微循环;能降低血小板表面活性,抑制血小板凝集,预防血栓的形成;所含阿魏酸的中性成分小剂量促进、大剂量抑制子宫平滑肌;水煎剂对动物中枢神经系统有镇静作用,并有明显而持久的降压作用;可加速骨折局部血肿的吸收,促进骨痂形成;有抗维生素E缺乏作用;能抑制多种杆菌;有抗组织胺和利胆作用。小鼠静注川芎嗪的LD50为239m/kg,每日给狗静滴5mg/kg、10mg/kg,连续给药4星期,丙氨酸转氨酶、血中非蛋白氮、血象及凝血时间均波动在正常指数范围内。实验结束时,取心、肝、脾、肺、肾、肠系膜淋巴结、肾上腺等做病理检查,均未见显著改变。兔血体外试验,2mg/ml川芎嗪未见溶血,给家免静滴100mg/kg亦未出现溶血现象。川芎(日本产)甲醇提取物给雄性wistar大鼠和ddy小鼠1次灌服6g/kg未见明显毒性,而腹腔注射相同剂量则表现一定毒性反应。给雄性wistar大鼠每日服甲醇提取物 1.5g/kg和3g/kg,连续21d,可见竖毛或流涎,红细胞对渗透压的抵抗力稍有提高,虽然病理观察未见肝脏病变,但肝重量增加,肝药酶活性诱导增强,血清中游离胆固醇和肾脏细胞色素P-450含量升高。
一种用于心梗脑梗患者的急救喷雾剂的制备方法,包括按照相应比例选取樟脑、桂枝、人参和川芎混合、打成粉、在溶剂中密封浸泡,获得成品。
所述溶剂为白酒。
所述白酒的酒精浓度为30度。
所述樟脑、桂枝、人参和川芎总质量与溶剂的质量比为10-77份:0.6-5 斤。
所述密封浸泡30-35天。
一种用于心梗脑梗患者的急救喷雾剂的应用,所述该喷雾剂在心梗脑梗患者倒地时做急救的应用。
本发明的有益效果为:
本发明提供了一种用于心梗脑梗患者的急救喷雾剂。在中医认为心梗属于气滞血瘀证,是寒凝心脉致心阳脱。用活血化瘀,散寒宣痹,通络止痛,回阳救逆的药物方可解此病症。本发明提供的该急救喷雾剂是以樟脑:辛热,归心经。能散寒止痛,其芳香能开窍醒脑;桂枝:性温,归心肺膀胱经,能解肌温通经络,助阳化气;人参:性温,归心肺脾肾经。能大补元气,强心化瘀,安神,回阳,固脱;川芎:性辛温,归肝胆心包经,行气开郁。活血化瘀,袪风止痛。再用30度的白酒浸泡一个月,就能使上述中药的疗效倍增。白酒本身就有疗效,发酵的白酒穿透力强,作用快,能扩张血管,活血化瘀,适量还能提神醒脑回阳。
该种治疗原理是人体皮肤是人体最大的一个营养交换嚣官。人能通过皮肤排泄体内的毒素,吸收空气中的氧气及其他营养素,还能排出二氧化碳等代谢产物,皮肤有很多细小的汗孔,平时皮肤都是处于封闭状态保护我们的身体不受外来物质的损坏。当外来刺激,如热,冷,痛都会作出反应。夏天热刺激后就会张开小孔排汗,带走身体内部的高热,调节体温。利用这一原理用酒精的刺激作用大,发酵后分子变小渗透力强的功效,再把药物带快速进入皮下及全身,达到急救的功效。让病人快速苏醒,恢复生命体征。
本发明提供的该喷雾剂,能随身带,能简单易行,人人都会操作,疗效显著,保证了病人的黄金抢救时间,提高了病人的抢救成率。
具体实施方式
下面结合具体实施例对本发明做进一步阐释。本领域技术人员将会理解,下列所描述的实施例是本发明一部分实施例,而不是全部的实施例,仅用于说明本发明,而不应视为限制本发明的范围。所用试剂均为可以通过市售购买获得的常规产品。
实施例1:
一种用于心梗脑梗患者的急救喷雾剂的制备方法,包括按照相应比例选取樟脑0.5克、桂枝10克、人参5克和川芎10克混合、打成粉、在30度白酒中密封浸泡30天,获得成品。用喷雾剂瓶子装好,一喷即可使用。
实施例2:
一种用于心梗脑梗患者的急救喷雾剂的制备方法,包括按照相应比例选取樟脑4克、桂枝50克、人参30克和川芎50克混合、打成粉、在30度白酒中密封浸泡35天,获得成品。用喷雾剂瓶子装好,一喷即可使用。
实施例3:
一种用于心梗脑梗患者的急救喷雾剂的制备方法,包括按照相应比例选取樟脑1克、桂枝20克、人参10克和川芎20克混合、打成粉、在30度白酒中密封浸泡30天,获得成品。用喷雾剂瓶子装好,一喷即可使用。
实施例4:
一种用于心梗脑梗患者的急救喷雾剂的制备方法,包括按照相应比例选取樟脑3克、桂枝35克、人参20克和川芎35克混合、打成粉、在30度白酒中密封浸泡35天,获得成品。用喷雾剂瓶子装好,一喷即可使用。
实施例5:
一种用于心梗脑梗患者的急救喷雾剂的制备方法,包括按照相应比例选取樟脑2克、桂枝30克、人参15克和川芎30克混合、打成粉、在30度白酒中密封浸泡30天,获得成品。用喷雾剂瓶子装好,一喷即可使用。
服用方式:规格是15毫升/瓶。成人一次用半瓶,如病情重隔二分钟再喷一次。一次可用1-2瓶。小孩根据年龄减量。只限外用,不必要口服。
临床验证:发明人长期用这药方的白酒浸泡液外喷濒死病人的心肺复苏,疗效显著。
本发明不局限于上述可选的实施方式,任何人在本发明的启示下都可得出其他各种形式的产品,均属于本发明的保护范围。上述具体实施方式不应理解成对本发明的保护范围的限制,本领域的普通技术人员应当理解,在不背离本发明的范围下,可对前述各实施例所记载的技术方案进行修改,或对其中部分或者全部技术特征进行等同替换,与此同时这些修改或者替换,并不会使相应的技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (9)
1.一种用于心梗脑梗患者的急救喷雾剂,其特征在于,所述喷雾剂主要由以下质量份数的原料制备得到:
樟脑0.5-4份,桂枝10-50份,人参5-30份和川芎10-50份。
2.根据权利要求1所述的一种用于心梗脑梗患者的急救喷雾剂,其特征在于,所述喷雾剂主要由以下质量份数的原料制备得到:
樟脑1-3份,桂枝20-35份,人参10-20份和川芎20-35份。
3.根据权利要求2所述的一种用于心梗脑梗患者的急救喷雾剂,其特征在于,所述喷雾剂主要由以下质量份数的原料制备得到:
樟脑2份,桂枝30份,人参15份和川芎30份。
4.采用权利要求1-3任一所述的一种用于心梗脑梗患者的急救喷雾剂的制备方法,其特征在于,包括按照相应比例选取樟脑、桂枝、人参和川芎混合、打成粉、在溶剂中密封浸泡,获得成品。
5.根据权利要求4所述的一种用于心梗脑梗患者的急救喷雾剂的制备方法,其特征在于,所述溶剂为白酒。
6.根据权利要求5所述的一种用于心梗脑梗患者的急救喷雾剂的制备方法,其特征在于,所述白酒的酒精浓度为30度。
7.根据权利要求4所述的一种用于心梗脑梗患者的急救喷雾剂的制备方法,其特征在于,所述樟脑、桂枝、人参和川芎总质量与溶剂的质量比为10-77份:0.6-5斤。
8.根据权利要求4所述的一种用于心梗脑梗患者的急救喷雾剂的制备方法,其特征在于,所述密封浸泡30-35天。
9.一种用于心梗脑梗患者的急救喷雾剂的应用,其特征在于,所述该喷雾剂在心梗脑梗患者倒地时做急救的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110796497.2A CN113456589A (zh) | 2021-07-14 | 2021-07-14 | 一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110796497.2A CN113456589A (zh) | 2021-07-14 | 2021-07-14 | 一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113456589A true CN113456589A (zh) | 2021-10-01 |
Family
ID=77878486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110796497.2A Pending CN113456589A (zh) | 2021-07-14 | 2021-07-14 | 一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113456589A (zh) |
-
2021
- 2021-07-14 CN CN202110796497.2A patent/CN113456589A/zh active Pending
Non-Patent Citations (1)
Title |
---|
张春荣: ""参桂胶囊治疗终末期肾病伴心力衰竭临床研究",张春荣,《中医学报》,第28卷第5期,第740-741页", 《中医学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101926900B (zh) | 一种足浴组合物及其制备方法 | |
KR100574097B1 (ko) | 숙취해소 및 간기능 개선용 식품 조성물 | |
CN107951966B (zh) | 一种中藏药结合的浴足液 | |
CN102727661A (zh) | 一种解酒保肝护肝胶囊及其制备方法 | |
WO2015018124A1 (zh) | 一种降血压中药制剂及其制备方法 | |
CN108143977A (zh) | 一种多功能保健药酒 | |
CN104225147B (zh) | 一种育发液 | |
CN104207567B (zh) | 一种多功能保健药枕及其制作方法 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN110538308B (zh) | 一种生发的中药组合物及其制备方法 | |
CN113456589A (zh) | 一种用于心梗脑梗患者的急救喷雾剂及其制备方法和应用 | |
CN102846113A (zh) | 一种桑叶保健枕芯及其制备方法 | |
CN103798472B (zh) | 一种保健茶及保健养生制剂 | |
CN105833172A (zh) | 用于治疗无症状性心肌缺血的中药冲剂及制备方法 | |
CN102266427A (zh) | 一种用于美容养颜的鹿茸当归酒及其制备方法和应用 | |
CN105031170A (zh) | 一种保健足浴粉及其制备方法 | |
CN102949466A (zh) | 升阳固脱浴足液 | |
CN104435798A (zh) | 改善神经衰弱的中药制剂及其制备方法 | |
CN108853413A (zh) | 一种具有益气补血功效的药食同源组合物及其制备方法 | |
CN107519279A (zh) | 一种具有解酒、护肝作用的中药组合物、解酒凝胶珠及其制备方法 | |
CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 | |
CN105327145A (zh) | 治疗高血压性脑出血的组合物及其制备方法 | |
CN104435589A (zh) | 一种治疗偏头痛的中药制剂及其制备方法 | |
ANTON et al. | THE MEDICINAL RELEVANCE OF USING “OFFICINALE “AND “OFFICINALIS “AS PLANT SPECIES NAMES IN ROMANIAN FLORA | |
CN104357290A (zh) | 补益延龄养生中药酒及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211001 |